Literature DB >> 31624865

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Gary J R Cook1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31624865     DOI： 10.1007/s00259-019-04540-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  The CT flare response of metastatic bone disease in prostate cancer.

Authors:  Christina Messiou; Gary Cook; Alison H M Reid; Gerhardt Attard; David Dearnaley; Johann S de Bono; Nandita M de Souza
Journal:  Acta Radiol       Date:  2011-03-23       Impact factor: 1.990

2.  FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy.

Authors:  Ora Israel; Anat Goldberg; Alicia Nachtigal; Daniela Militianu; Rachel Bar-Shalom; Zohar Keidar; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-22       Impact factor: 9.236

3.  Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Authors:  Fannie Morin; Jean-Mathieu Beauregard; Michelle Bergeron; Molière Nguile Makao; Louis Lacombe; Vincent Fradet; Yves Fradet; Frédéric Pouliot
Journal:  Eur Urol Focus       Date:  2017-02-23

4.  Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.

Authors:  Bo Chen; Peng Wei; Homer A Macapinlac; Yang Lu
Journal:  Nucl Med Commun       Date:  2019-09       Impact factor: 1.690

5.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

6.  The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.

Authors:  Gerald L Andriole; Lale Kostakoglu; Albert Chau; Fenghai Duan; Umar Mahmood; David A Mankoff; David M Schuster; Barry A Siegel
Journal:  J Urol       Date:  2019-02       Impact factor: 7.450

7.  Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Authors:  Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

8.  The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2009-07-09       Impact factor: 3.488

9.  PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models.

Authors:  Shuntaro Oka; Masaru Kanagawa; Yoshihiro Doi; David M Schuster; Mark M Goodman; Hirokatsu Yoshimura
Journal:  Theranostics       Date:  2017-05-15       Impact factor: 11.556
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.